Risk factors

Protalix relies heavily on commercial partners Chiesi and Pfizer for revenue from its marketed products Elfabrio and Elelyso. The company faces significant manufacturing, regulatory, and collaboration risks, including a breach by its Brazilian distributor Fiocruz. Protalix holds $227.2 million in net operating loss carryforwards subject to potential ownership change limits.

ProKidney has no revenue and recurring net losses, reporting $163.3 million in net losses for 2024. The business depends entirely on developing and commercializing its lead cell therapy candidate, rilparencel, for chronic kidney disease. Manufacturing is complex, centralized in Winston-Salem, and relies on patient-specific autologous cells and specialized cryopreservation.

Quanterix faces concentration risks around its upcoming Akoya merger, single-source instrument manufacturers, and a reliance on key customers and neurological assays.

RBB Bancorp relies heavily on Asian-American immigrant clients, commercial real estate, and non-qualified single-family residential mortgages. High geographic concentration in California exposes the bank to regional economic, environmental, and regulatory shocks.

Vicarious Surgical has $48.8 million in cash and short-term investments funding operations only into the first quarter of 2026. The company has earned zero revenues and accumulated a deficit of $195.9 million since inception. The Vicarious Surgical System faces regulatory, clinical development, manufacturing, and intensive market competition risks.

Rocky Brands faces concentrated risks around international manufacturing, reliance on key wholesale customers, and ongoing IT and ERP system implementations.

SAIC relies almost exclusively on U.S. government contracts, generating 98 percent of its revenues from them. The company faces heavy competition, stringent regulatory oversight, and growing exposure to cyber and AI execution risks.

Sana Biotechnology faces significant clinical and commercial risks centered on cell therapy development, complex biologic manufacturing, and intellectual property protection. The company has undergone multiple workforce reductions and strategic restructurings, including shifting its fusogen platform focus.

Interest rate changes by the Federal Reserve heavily impact net interest income and mortgage banking revenues. Geographic concentration in Tennessee, Alabama, and Florida links financial results to local economic conditions. Commercial real estate loans and large borrower relationships present concentration risks to asset quality.

Senior living operations face heavy debt loads, private pay reliance, and intense labor competition. Capital needs and joint venture dependencies shape ongoing expansion strategies.

Sable Offshore relies entirely on restarting production of the SYU Assets in California, requiring $152.0 million and regulatory approvals.

Turtle Beach relies heavily on a top five retail customer concentration representing 69% of gross sales in 2024. The company depends on third-party console platforms like Microsoft Xbox and Sony PlayStation. Financing relies on debt facilities from Bank of America and Blue Torch carrying liens on assets.